Our CEO, Chris Molloy, has an article featured at Open Access Government. He discusses how new approaches, tools and technologies are needed:
“Despite the greatest explosion in ‘new’ biology in 50 years, pharma R&D productivity has been falling for a decade. According to an annual survey by Deloitte, the top 10 global pharma companies now have a return on their R&D investment of only 3.4% and spiralling R&D costs. Stand up the SME sector. Traditionally the agile, risk-taking tester of new ideas, primed to be bought, incorporated into a bigger firm or to see their product developed by others, the SME now has a new opportunity: to grow.”
Read the full article at Open Access Government.
